"We are proud of our product pipeline, which is a testament to Ralf's strategy and vision, and we thank him for developing a promising pipeline of product candidates, including two which are in late-stage development," commented Daniel Tasse, Chairman and CEO of Ikaria. "However, I am delighted that Doug has joined us, and am confident that we will benefit greatly from his knowledge, experience and leadership in driving the further development of our early- and late-stage pipeline, which we believe will help us achieve our vision of becoming a leader in critical care."
Dr. Greene has over 30 years of experience in academia, and 10 years of experience in the pharmaceutical industry. He joins Ikaria from sanofi-aventis, where he served in various leadership roles since 2003, including Chief Medical Officer of its U.S. business from 2006-2009. Dr. Greene was a member of the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drug Advisory Committee from 1988-1994, and acted as Chairman of the Advisory Committee from 1990-1994.
About Ikaria, Inc.
Ikaria, Inc. is a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to address the significant unmet needs of critically ill patients. The company's lead product is INOtherapy®, an all-inclusive offering of drug product, services and technologies. INOMAX® (nitric oxide) for inhalation, the drug included in the INOtherapy offering, is the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. INOtherapy also is marketed in Puerto Rico, Canada, Australia, Mexico and Japan. Ikaria acquired the North American and Australian rights to LUCASSIN® (terlipressin), a potential treatment for hepatorenal syndrome Type 1, as well as the exclusive worldwide license to IK-5001, a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. The company also has a number of investigational compounds in development. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. Please visit www.ikaria.com.
SOURCE Ikaria Holdings, Inc.
